# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Edward W. Brooke (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML014-SYN
- Date: 2026-01-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Howard Bellamy, MD
- Calendar frame: modern shifted

## What we are working on

- Wants his breast cancer follow-up and tamoxifen managed close to home after his surgery and the start of tamoxifen at another hospital **S**
- Had not known that men could get breast cancer and dismissed his first symptom as aging or a strained muscle; wants to understand his risk of recurrence and what it means for his family **S**

## Your goals

- Take tamoxifen every day with side effects managed, aiming to continue for at least five years. Target: 2026-08-11. Recorded outcome: No missed doses by pill count over seven months; mild hot flashes and a mild fall in libido, both manageable; no clot symptoms. **S**
- Complete germline genetic testing with counseling, and give him written information for his relatives. Target: 2026-05-12. Recorded outcome: No pathogenic variant in a multigene panel; family letter given. **S**
- Establish bone health on hormone therapy at his age: DXA, vitamin D of 30 ng/mL or more, and weight-bearing exercise. Target: 2026-05-12. Recorded outcome: Femoral neck T-score -1.2; vitamin D 36 ng/mL after supplementation. **S**
- Give a written survivorship care plan with the surveillance schedule. Target: 2026-08-11. Recorded outcome: Survivorship care plan given at the survivorship visit. **S**

## What we agreed to do

- Medical oncology consultation to take over adjuvant endocrine therapy, confirm that no further adjuvant treatment is needed, and arrange germline genetic testing. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 5.2025 (2025) **S**
- Tamoxifen 20 mg daily for an initial five years, with venous thromboembolism symptoms, mood, hot flashes, sexual side effects, adherence, and interacting medicines reviewed at every visit. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Genetic counseling and germline multigene panel testing (including BRCA2, BRCA1, PALB2, CHEK2, and ATM), with a letter for first-degree relatives explaining the result. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); Bedrosian I, et al. Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline. J Clin Oncol 2024;42(5):584-604 (2024) **S**
- Bone health: DXA at baseline, vitamin D repletion, dietary calcium, and weight-bearing exercise; bone-modifying drugs only for osteoporosis, not to prevent recurrence. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); Shapiro CL, et al. Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline (2019); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Survivorship surveillance: cancer-related history and examination of both sides of the chest wall and both axillae every 3 to 6 months for 3 years, then every 6 to 12 months to 5 years, then yearly; no routine imaging, blood tests, or tumor markers without symptoms; lymphedema checks. Guideline: Hassett MJ, et al. Management of Male Breast Cancer: ASCO Guideline. J Clin Oncol 2020;38(16):1849-1863 (2020); Runowicz CD, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**
- Distress screening at each visit, at least 150 minutes of activity a week, and a written survivorship care plan. Guideline: Runowicz CD, et al. American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline. CA Cancer J Clin 2016;66(1):43-73 (2016); CMID: Clinical Monitoring Intelligence Database, breast cancer monograph (2026) **S**

## Follow-up

- 2026-01-13: First visit to establish shared care for breast cancer on adjuvant tamoxifen, fourteen weeks after bilateral mastectomy and right axillary dissection **S**
- 2026-02-10: Four-week follow-up with medical oncology consultation: adjuvant plan, germline testing, tamoxifen safety, and bone density results **S**
- 2026-05-12: Three-month follow-up: germline result, tamoxifen side effects and adherence, vitamin D recheck **S**
- 2026-08-11: Survivorship visit: cancer-related history and examination, tamoxifen review, and written survivorship care plan **S**
- 2026-10-13: Subsequent annual wellness visit **S**

This teaching document does not replace care from a qualified clinician.
